Twist Bioscience posts strong 23% revenue growth despite wider-than-expected quarterly loss

Twist Bioscience reported a quarterly loss of $0.56 per share, missing analyst expectations, but achieved strong revenue growth of $118.4 million, a 23% increase year-over-year. This marks the company's 14th consecutive quarter of revenue growth, driven by gains in DNA Synthesis, Protein Solutions, and Next-Generation Sequencing segments. Despite the earnings miss, the company maintains a healthy financial position with low debt and strong liquidity, though it remains unprofitable as reflected by its negative P/E ratio. The results highlight ongoing demand for its biotechnology products and potential for future growth as it focuses on AI-enabled discovery.